Brand Reference: Jardiance
| Metric | Verified Benchmark | Source |
|---|---|---|
| Empagliflozin RxNorm Concept ID | 1545653 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $18.9200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $612.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $89.00 / mo (Direct TeleMed) | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $115.00 / mo | 19 Zero-PHI Verified Patient Logs |
Competitively blocks sodium-glucose co-transporter 2 in the S1 segment of the proximal renal tubule, inducing 60–80 g/day urinary glucosuria and natriuresis, restoring tubuloglomerular feedback, lowering intraglomerular pressure, and shifting myocardial fuel utilization toward beta-hydroxybutyrate.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Empagliflozin (Jardiance, RxCUI 1545653) at $18.9200 per unit, whereas walk-in chain pharmacies bill cash patients an average of $612.00 monthly—creating a 81% ($497.00/mo) wholesale arbitrage spread down to $115.00.
Systemic exposure to Empagliflozin reflects ~78% oral absorption kinetics and glucuronidation via ugt2b7, ugt1a3, ugt1a8, and ugt1a9 without major cyp450 involvement, sustaining receptor engagement across a 12.4 hours half-life window (1.5 hours to peak glucosuria response profile).
Dosing protocols (10 mg PO once daily or 25 mg PO once daily) balance efficacy (86.50% patient satisfaction across 19 logs) against osmotic polyuria (22% of reports), mycotic genital candidiasis (11% of reports), mild postural lightheadedness (7% of reports), with strict avoidance in dialysis or end-stage renal failure; history of euglycemic ketoacidosis on sglt2 therapy.
Across 19 verified cash-pay logs, Empagliflozin achieves a 86.50% Worth-It rating with out-of-pocket spend averaging $115.00/mo versus $612.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cash Clinic at 10 mg PO once daily for Empagliflozin; monthly out-of-pocket dropped to $101.20 compared with $612.00 retail.
Completed 10 weeks on Empagliflozin (25 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 10 mg PO once daily Empagliflozin sourced via Local Pharmacy ($133.40/mo cash pay without insurance prior authorization).